Muscarinic M1 receptor agonists: Can they improve cognitive performance?

International Journal of Neuropsychopharmacology

Volumn 16, Issue 4, 2013, Pages 717-720

  Scarr, Elizabeth ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GSK 1034702; MUSCARINIC M1 RECEPTOR AGONIST; UNCLASSIFIED DRUG; XANOMELINE; BENZIMIDAZOLE DERIVATIVE; MUSCARINIC M1 RECEPTOR;

ALLOSTERISM; ALZHEIMER DISEASE; COGNITION; COGNITIVE DEFECT; DOSE RESPONSE; DRUG BINDING SITE; DRUG DESIGN; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPEPSIA; HUMAN; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SMOKING CESSATION; UNCONSCIOUSNESS; VOMITING; ADDICTION; AGONISTS; EPISODIC MEMORY; MALE; PSYCHOLOGY; DRUG POTENTIATION; NOTE; PSYCHOLOGICAL ASPECT;

BEHAVIOR, ADDICTIVE; BENZIMIDAZOLES; COGNITION DISORDERS; HUMANS; MALE; MEMORY, EPISODIC; RECEPTOR, MUSCARINIC M1; SMOKING CESSATION;

EID: 84875694713     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712001113     Document Type: Review

References (41)

1. Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, et al. (2003). Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nature Neuroscience 6, 51-58.
2. Araujo DM, Lapchak PA, Robitaille Y, Gauthier S, et al. (1988). Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. Journal of Neurochemistry 50, 1914-1923.
3. Bodick NC, Offen WW, Levey AI, Cutler NR, et al. (1997). Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Archives of Neurology 54, 465-473.
4. Bradley SR, Lameh J, Ohrmund L, Son T, et al. (2010). AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. Neuropharmacology 58, 365-373.
5. Brady AE, Jones CK, Bridges TM, Kennedy JP, et al. (2008). Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. Journal of Pharmacology and Experimental Therapeutics 327, 941-953.
6. Budzik B, Garzya V, Shi D, Walker G, et al. (2010). Novel N-substituted benzimidazolones as potent, selective, CNS-penetrant, and orally active M1 mAChR agonists. ACS Medicinal Chemistry Letters 1, 244-248.
7. Bymaster FP, McKinzie DL, Felder CC, Wess J (2003). Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochemistry Research 28, 437-442.
8. Bymaster FP, Whitesitt CA, Shannon HE, DeLapp N, et al. (1997). Xanomeline: a selective muscarinic agonist for the treatment of Alzheimer's disease. Drug Development Research 40, 158-170.
9. Chan WY, McKinzie DL, Bose S, Mitchell SN, et al. (2008). Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proceedings of the National Academy of Sciences USA 105, 10978-10983.
10. Clark AL, Mitchelson F (1976). The inhibitory effect of gallamine on muscarinic receptors. British Journal of Pharmacology 58, 323-331.
11. Coyle JT, Price DL, Mahlon RD (1983). Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219, 1184-1190.
12. Dean B, McLeod M, Keriakous D, McKenzie J, et al. (2002). Decreased muscarinic(1) receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Molecular Psychiatry 7, 1083-1091.
13. Digby GJ, Noetzel MJ, Bubser M, Utley TJ, et al. (2012). Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models. Journal of Neuroscience 32, 8532-8544.
14. Dilsaver SC (1986). Cholinergic mechanisms in depression. Brain Research 396, 285-316.
15. Giessel AJ, Sabatini BL (2010). M1 muscarinic receptors boost synaptic potentials and calcium influx in dendritic spines by inhibiting postsynaptic SK channels. Neuron 68, 936-947.
16. Harrison PJ, Barton AJ, Najlerahim A, McDonald B, et al. (1991). Increased muscarinic receptor messenger RNA in Alzheimer's disease temporal cortex demonstrated by in situ hybridization histochemistry. Brain Research Molecular Brain Research 9, 15-21.
17. Jones CK, Brady AE, Davis AA, Xiang Z, et al. (2008). Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. Journal of Neuroscience 28, 10422-10433.
18. Langmead CJ, Watson J, Reavill C (2008). Muscarinic acetylcholine receptors as CNS drug targets. Pharmacology and Therapeutics 117, 232-243.
19. Leach K, Loiacono RE, Felder CC, McKinzie DL, et al. (2010). Molecular mechanisms of action and in vivo validation of an m(4) muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 35, 855-869.
20. Lewis LM, Bridges TM, Niswender CM, Weaver CD, et al. (2010). Discovery of a highly selective in vitro and in vivo M4 positive allosteric modulator (PAM). Probe Reports from the NIH Molecular Libraries Program (http://www.ncbi.nlm.nih.gov/books/NBK50687/). Accessed 8 October 2010.
21. Mancama D, Arranz MJ, Landau S, Kerwin R (2003). Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. American Journal of Medical Genetics, B Neuropsychiatric Genetics 119, 2-6.
22. Marlo JE, Niswender CM, Days EL, Bridges TM, et al. (2009). Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Molecular Pharmacology 75, 577-588.
23. 1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. International Journal of Neuropsychopharmacology. Published online: 29 August 2012. doi:10.1017/S1461145712000752.
24. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, et al. (2004). Identification of separable cognitive factors in schizophrenia. Schizophrenia Research 72, 29-39.
25. Overk CR, Felder CC, Tu Y, Schober DA, et al. (2010). Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease. Journal of Chemical Neuroanatomy 40, 63-70.
26. Raedler TJ, Bymaster FP, Tandon R, Copolov D, et al. (2006). Towards a muscarinic hypothesis of schizophrenia. Molecular Psychiatry 12, 232-246.
27. Reid PR, Bridges TM, Sheffler DJ, Cho HP, et al. (2011). Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe. Bioorganic and Medicinal Chemistry Letters 21, 2697-2701.
28. Ruberg M, Ploska A, Javoy-Agid F, Agid Y (1982). Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia. Brain Research 232, 129-139.
29. Scarr E, Cowie TF, Kanellakis S, Sundram S, et al. (2009). Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Molecular Psychiatry 14, 1017-1023.
30. Shannon HE, Bymaster FP, Calligaro DO, Greenwood B, et al. (1994). Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors. Journal of Pharmacology and Experimental Therapeutics 269, 271-281.
31. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, et al. (2008). Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. American Journal of Psychiatry 165, 1033-1039.
32. Shiozaki K, Iseki E, Hino H, Kosaka K (2001). Distribution of m1 muscarinic acetylcholine receptors in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies-an immunohistochemical study. Journal of the Neurological Sciences 193, 23-28.
33. Shirey JK, Brady AE, Jones PJ, Davis AA, et al. (2009). A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. Journal of Neuroscience 29, 14271-14286.
34. Spalding TA, Ma JN, Ott TR, Friberg M, et al. (2006). Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation. Molecular Pharmacology 70, 1974-1983.
35. Tucek S, Proska J (1995). Allosteric modulation of muscarinic acetylcholine receptors. Trends in Pharmacological Sciences 16, 205-212.
36. Valant C, Felder CC, Sexton PM, Christopoulos A (2012). Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects. Molecular Pharmacology 81, 41-52.
37. 1 receptor agonist, AC-260584. Behavioural Neuroscience 122, 570-575.
38. Watson J, Brough S, Coldwell MC, Gager T, et al. (1998). Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. British Journal of Pharmacology 125, 1413-1420.
39. Zavitsanou K, Katsifis A, Mattner F, Xu-Feng H (2004). Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 29, 619-625.
40. Zhang Y, Dyck RH, Hamilton SE, Nathanson NM, et al. (2005). Disrupted tonotopy of the auditory cortex in mice lacking M1 muscarinic acetylcholine receptor. Hearing Research 201, 145-155.
41. Zhang Y, Hamilton SE, Nathanson NM, Yan J (2006). Decreased input-specific plasticity of the auditory cortex in mice lacking M1 muscarinic acetylcholine receptors. Cerebral Cortex 16, 1258-1265.